|
Pfizer receives Breakthrough Therapy designation from FDA for PF-04965842, an oral JAK1 Inhibitor, for the treatment of patients with moderate-to-severe atopic dermatitis
|
14 February 2018 |
|
Pfizer announces positive top-line results for potential biosimilar to Rituxan® / MabThera®
|
25 January 2018 |
|
FDA approves new Pfizer biosimilar
|
15 December 2017 |
|
Pfizer enters into agreement to develop and commercialize CRESEMBA® (isavuconazole) in China and Asia Pacific region
|
01 December 2017 |
|
Pfizer receives FDA approval for SUTENT® (sunitinib malate) as first and only adjuvant treatment for adult patients at high risk of recurrent renal cell carcinoma
|
16 November 2017 |
|
Spark Therapeutics and Pfizer amend license agreement for investigational SPK-9001 in hemophilia B
|
08 November 2017 |
|
The Union for International Cancer Control and Pfizer award new round of grants totalling US$500,000 to organisations in 19 countries
|
23 October 2017 |
|
Pfizer reviewing strategic alternatives for Consumer Healthcare business
|
12 October 2017 |
|
Pfizer launches novel programs to put important support services at the fingertips of cancer patients
|
05 October 2017 |
|
Pfizer goes to Court to allow competition for biologics and expand options for patients
|
20 September 2017 |
|
Alliance Foundation Trials opens global trial investigating first-in-class palbociclib in HR+, HER2+ metastatic breast cancer
|
23 August 2017 |
|
FDA Advisory Committee votes in favor of XELJANZ® (tofacitinib citrate) for the treatment of active psoriatic arthritis
|
04 August 2017 |
|
Pfizer announces positive top-line results from the comparative REFLECTIONS B7391003 study for PF-06439535, a potential biosimilar to Avastin® (bevacizumab)
|
25 July 2017 |
|
Merck and Pfizer collaborate with Corning
|
20 July 2017 |
|
FDA Advisory Committee votes in favor of Pfizer's MYLOTARG (gemtuzumab ozogamicin) for acute myeloid leukemia
|
13 July 2017 |
|
BESPONSA® approved in the EU for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia
|
07 July 2017 |
|
Pfizer breaks ground on new R&D facility in Chesterfield, Missouri
|
28 June 2017 |
|
Pfizer and Lilly receive FDA Fast Track designation for tanezumab
|
13 June 2017 |
|
Pfizer receives FDA Fast Track designation for tafamidis for transthyretin cardiomyopathy
|
06 June 2017 |
|
FDA Advisory Committee recommends approval of Pfizer's proposed biosimilar to Epogen® / Procrit® across all indications
|
25 May 2017 |